Gur Roshwalb

CEO
1E Therapeutics

​

Dr. Gur Roshwalb is the CEO of 1E Therapeutics, an Israeli biotech company developing a new modality of RNA interference with broad potential in allele specific diseases. Prior to 1E, Gur was a partner at aMoon, where he lead biotech investing efforts and was a board member of several portfolio companies of aMoon Growth. Prior to joining aMoon, he was CEO at several private and public biotech companies. Earlier, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. Gur started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he also served as Chief Resident.
Gur obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business, and a B.A. from Columbia University.

 

Speech title & Synopsis

Panel Discussion 2: Global Investment Trend

as Moderator